	US 12,226,464 B2
	Compositions for treating addiction
Joan M. Fallon, White Plains, NY (US); and Matthew F. Heil, Sherman, CT (US)
Assigned to Curemark, LLC, Rye Brook, NY (US)
Appl. No. 16/499,988
Filed by Curemark, LLC, Rye Brook, NY (US)
PCT Filed Apr. 10, 2018, PCT No. PCT/US2018/026841 § 371(c)(1), (2) Date Oct. 1, 2019, PCT Pub. No. WO2018/191233, PCT Pub. Date Oct. 18, 2018.
Claims priority of provisional application 62/483,856, filed on Apr. 10, 2017.
Prior Publication US 2020/0101145 A1, Apr. 2, 2020
Int. Cl. A61K 38/54 (2006.01); A61K 9/48 (2006.01); A61K 9/50 (2006.01); A61P 25/36 (2006.01); A61K 45/06 (2006.01)

CPC A61K 38/54 (2013.01) [A61K 9/4808 (2013.01); A61K 9/4825 (2013.01); A61K 9/4891 (2013.01); A61K 9/5015 (2013.01); A61P 25/36 (2018.01); A61K 45/06 (2013.01)]

35 Claims

1. A method of reducing an elevated amount of ΔFos in a subject having an addiction, wherein ΔFos is elevated in the subject due to the addiction compared to a subject without the addiction, the method comprising: ¶

(a) selecting the subject to be treated when the subject is diagnosed with a blood level of phenylalanine of from 1 mg/dL to 3 mg/dL or with a blood level of phenylalanine of from 60 to 120 micromolar, and

(b) administering to the subject a therapeutically effective amount of a pharmaceutical composition that comprises digestive enzymes, wherein ΔFos is reduced upon administration of the pharmaceutical composition to the subject.